U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula C28H31N5O
Molecular Weight 453.5786
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ADW-742

SMILES

NC1=C2C(=CN([C@H]3C[C@H](CN4CCCC4)C3)C2=NC=N1)C5=CC=CC(OCC6=CC=CC=C6)=C5

InChI

InChIKey=LSFLAQVDISHMNB-AFARHQOCSA-N
InChI=1S/C28H31N5O/c29-27-26-25(22-9-6-10-24(15-22)34-18-20-7-2-1-3-8-20)17-33(28(26)31-19-30-27)23-13-21(14-23)16-32-11-4-5-12-32/h1-3,6-10,15,17,19,21,23H,4-5,11-14,16,18H2,(H2,29,30,31)/t21-,23-

HIDE SMILES / InChI

Molecular Formula C28H31N5O
Molecular Weight 453.5786
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

NVP-ADW742 is a novel small weight molecular inhibitor of insulin-like growth factor-1 receptor (IGF-IR), which is investigated for treatment of different types of cancers.

Originator

Curator's Comment: # Novartis Pharma AG

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
The insulin-like growth factor-I receptor kinase inhibitor NVP-ADW742 sensitizes medulloblastoma to the effects of chemotherapy.
2011-06
The insulin-like growth factor-1 receptor kinase inhibitor, NVP-ADW742, suppresses survival and resistance to chemotherapy in acute myeloid leukemia cells.
2010
The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.
2004-05

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
NVP-ADW742 significantly inhibits the serum-stimulated cell proliferation in a variety of tumor cell lines in dose-dependent manner, with IC50 values of 0.1-0.5 μM for the multiple myeloma (MM) cell lines, and the antitumor effects on MM cells can not be overcome by the co-culture with BMSCs. In addition, NVP-ADW742 is active against MM cell lines.
Substance Class Chemical
Created
by admin
on Mon Mar 31 23:31:10 GMT 2025
Edited
by admin
on Mon Mar 31 23:31:10 GMT 2025
Record UNII
MXS2N5862L
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ADW-742
Common Name English
GSK-552602A
Preferred Name English
NVP-ADW742
Code English
7H-PYRROLO(2,3-D)PYRIMIDIN-4-AMINE, 5-(3-(PHENYLMETHOXY)PHENYL)-7-(TRANS-3-(1-PYRROLIDINYLMETHYL)CYCLOBUTYL)-
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID70431367
Created by admin on Mon Mar 31 23:31:10 GMT 2025 , Edited by admin on Mon Mar 31 23:31:10 GMT 2025
PRIMARY
PUBCHEM
9825149
Created by admin on Mon Mar 31 23:31:10 GMT 2025 , Edited by admin on Mon Mar 31 23:31:10 GMT 2025
PRIMARY
FDA UNII
MXS2N5862L
Created by admin on Mon Mar 31 23:31:10 GMT 2025 , Edited by admin on Mon Mar 31 23:31:10 GMT 2025
PRIMARY
CAS
475488-23-4
Created by admin on Mon Mar 31 23:31:10 GMT 2025 , Edited by admin on Mon Mar 31 23:31:10 GMT 2025
PRIMARY
Related Record Type Details
ACTIVE MOIETY